Sunbird Bio

Our validated blood-based diagnostic platform has the potential to provide the broadest panel of diagnostics that empower researchers and clinicians with critical insights not readily available from current tests.   We’re working to enable earlier, more accurate diagnosis and treatment for patients with Alzheimer’s disease, Parkinson’s disease and other neurological disorders.  Learn more here: https://lnkd.in/ghx9B3VY  #innovation #Alzheimers #diagnostics #biotech #earlydiagnosis

#CONFERENCE: Our team will bring our #innovation to the world stage at this year’s Alzheimer's Association® International Conference®, where we’ll present the latest data on our tau detection capabilities with our blood-based diagnostic platform. We look forward to sharing and collaborating with our peers in the #Alzheimers space as we work to enable earlier, more accurate diagnosis and treatment of neurological disorders. Meet with our VP, Business Development Mario Morken and read more: https://bit.ly/464dLoa #AAIC24 #News

We're #hiring a new (Senior) Research Officer in Singapore to join our product development team. Apply today or share this post with your network!

Amyloid-related imaging abnormalities (ARIA), which can include brain swelling or bleeding, can occur in people with Alzheimer’s disease who are undergoing treatment. Currently, #ARIA can only be detected and monitored through MRI. Our pipeline includes an #innovative blood test for detecting the abnormalities associated with ARIA that could ultimately augment or replace MRI scans, offering hope for better patient outcomes. Learn more about our technology: https://lnkd.in/ghx9B3VY #diagnostics #biomarkers #biotechnews 

Our team at Sunbird Bio is proud to wear purple this month in recognition of Alzheimer's & Brain Awareness Month. We support the Alzheimer's Association®’s mission to #EndAlz and raise awareness for this deadly disease. #GoPurple #ABAM2024

#DYK the rate of undetected dementia is as high as 60%? Our CEO John McDonough recently sat down with The Pathologist where he explained why our APEX diagnostic platform has the potential to improve diagnostic accessibility for people with neurological disorders. Read more: https://lnkd.in/e57SUuQr  #dementia #alzheimers #diagnosticinnovation #biopharma 

We’re #hiring. Help us make a difference by being an instrumental member of our R&D team!

Dr. Nicholas Ho, our head of innovation and scientific co-founder, shares his perspective on why our protein- and blood-based diagnostics set us apart from the rest. Learn more about our #innovative technology, and its potential to provide superior disease detection: https://lnkd.in/ghx9B3VY #diagnostics #biotech 

  “We don’t just have an opportunity, we have an obligation to develop these tests and make them as accessible as we can in the US and around the world.” Our CEO John McDonough spoke with Pharmaceutical-Technology about our proprietary APEX diagnostic platform and its potential to provide unparalleled insights into neurological diseases like #Alzheimers via multiple key biomarkers.   Read more on why John emphasizes the need for blood tests that both diagnose disease and monitor progression: https://lnkd.in/exYxvbgC  #Tau #diagnostics #innovation #DementiaActionWeek #Dementia

In #AlzheimersDisease, #ParkinsonsDisease, and other neurological conditions, sticky proteins accumulate in the brain and cause cognitive decline. Only scarce levels of these important biomarkers can pass through the blood-brain barrier, making it difficult for most blood tests to accurately detect them.   That’s where our technology comes in. Studies have demonstrated that APEX can directly detect the specific protein cells that aggregate in the brain, including amyloid beta, tau, alpha synuclein, and other protein biomarkers, signaling the presence of disease.   An earlier diagnosis could mean more treatment options and better outcomes for patients.   Learn more: https://lnkd.in/esmps2zf  #biomarkers #innovation